Total Payments
$68,115
2024 Payments
$25,348
Companies
7
Transactions
71
Medicare Patients
515
Medicare Billing
$97,726
Payment Breakdown by Category
Research$56,535 (83.0%)
Consulting$9,135 (13.4%)
Travel$1,330 (2.0%)
Other$779.58 (1.1%)
Food & Beverage$335.81 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $56,535 | 52 | 83.0% |
| Consulting Fee | $9,135 | 4 | 13.4% |
| Travel and Lodging | $1,330 | 6 | 2.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $779.58 | 2 | 1.1% |
| Food and Beverage | $335.81 | 7 | 0.5% |
Payments by Type
Research
$56,535
52 transactions
General
$11,580
19 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $52,920 | 50 | $0 (2024) |
| Merck Sharp & Dohme LLC | $7,968 | 9 | $0 (2024) |
| Amgen Inc. | $3,813 | 3 | $0 (2024) |
| Eli Lilly and Company | $1,613 | 2 | $0 (2024) |
| Mirati Therapeutics, Inc. | $903.76 | 3 | $0 (2023) |
| Boehringer Ingelheim International GmbH | $779.58 | 2 | $0 (2022) |
| ARRAY BIOPHARMA INC | $117.58 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $25,348 | 20 | PFIZER INC. ($13,540) |
| 2023 | $11,325 | 14 | PFIZER INC. ($10,120) |
| 2022 | $8,742 | 11 | PFIZER INC. ($7,950) |
| 2021 | $15,419 | 16 | PFIZER INC. ($14,030) |
| 2020 | $7,280 | 10 | PFIZER INC. ($7,280) |
All Payment Transactions
71 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | — | In-kind items and services | $3,200.00 | Research |
| Study: BRAFTOVI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 11/04/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,710.00 | General |
| 11/04/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 10/24/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | — | In-kind items and services | $1,400.00 | Research |
| Study: BRAFTOVI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/17/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $356.67 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $163.64 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $40.99 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $31.99 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $269.00 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $192.00 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $53.99 | General |
| Category: ONCOLOGY | ||||||
| 09/24/2024 | PFIZER INC. | MEKTOVI, BRAFTOVI | — | In-kind items and services | $330.00 | Research |
| Study: PF07265807 CLINICAL PUBLICATION PROGRAM | ||||||
| 09/12/2024 | PFIZER INC. | MEKTOVI, BRAFTOVI | — | In-kind items and services | $3,200.00 | Research |
| Study: PF07265807 CLINICAL PUBLICATION PROGRAM | ||||||
| 09/10/2024 | PFIZER INC. | MEKTOVI, BRAFTOVI | — | In-kind items and services | $940.00 | Research |
| Study: PF07265807 CLINICAL PUBLICATION PROGRAM | ||||||
| 06/18/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $14.63 | General |
| Category: ONCOLOGY | ||||||
| 05/07/2024 | PFIZER INC. | MEKTOVI (Drug), BRAFTOVI | — | In-kind items and services | $330.00 | Research |
| Study: BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 04/05/2024 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 02/22/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 01/10/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | — | In-kind items and services | $3,200.00 | Research |
| Study: ENCORAFENIB PF07265807 BINIMETINIB MULTI PRODUCT CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/04/2024 | Amgen Inc. | LUMAKRAS (Drug) | — | In-kind items and services | $2,225.23 | Research |
| Study: AMG 510 Ph1b Master Protocol 20190135 • Category: Oncology | ||||||
| 11/17/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Consulting Fee | Cash or cash equivalent | $431.25 | General |
| Category: ONCOLOGY | ||||||
| 07/12/2023 | Amgen Inc. | — | Travel and Lodging | Cash or cash equivalent | $198.23 | General |
| 06/13/2023 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | — | In-kind items and services | $940.00 | Research |
| Study: ENCORAFENIB MULTI PRODUCT PF07265807 BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 06/06/2023 | ARRAY BIOPHARMA INC | MEKTOVI (Drug), BRAFTOVI | Food and Beverage | In-kind items and services | $102.95 | General |
| Category: ONCOLOGY | ||||||
| 06/04/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $78.76 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $27,990 | 31 |
| ENCORAFENIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $8,570 | 8 |
| BRAFTOVI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,600 | 2 |
| PF07265807 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,470 | 3 |
| ENCORAFENIB PF07265807 BINIMETINIB MULTI PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| AMG 510 Ph1b Master Protocol 20190135 | Amgen Inc. | $2,225 | 1 |
| ENCORAFENIB MULTI PRODUCT PF07265807 BINIMETINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,880 | 2 |
| AMG 510 - Adv. KRAS G12C solid tumors_20190135 | Amgen Inc. | $1,389 | 1 |
| NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| PF06804103 MAVELERTINIB PF4136309 PF06952229 NIROGACESTAT PF06671008 ARRY 382 PF04691502 PF06821497 PF06939999 PF06840003 PF07265807 COFETUZUMAB PELIDOTIN MULTI PRODUCT UTOMILUMAB GEDATOLISIB ELRANATAMAB PF067535 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| BINIMETINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 133 | 371 | $181,840 | $28,611 |
| 2022 | 4 | 131 | 359 | $178,065 | $28,508 |
| 2021 | 3 | 117 | 341 | $161,275 | $25,930 |
| 2020 | 6 | 134 | 274 | $102,235 | $14,676 |
Total Patients
515
Total Services
1,345
Medicare Billing
$97,726
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 41 | 143 | $77,935 | $12,085 | 15.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 61 | 159 | $59,625 | $8,275 | 13.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 53 | $27,560 | $5,643 | 20.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $16,720 | $2,607 | 15.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 48 | 158 | $86,110 | $13,713 | 15.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 55 | 139 | $52,125 | $7,958 | 15.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 48 | $25,200 | $4,446 | 17.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 14 | 14 | $14,630 | $2,390 | 16.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 47 | 172 | $93,740 | $14,997 | 16.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 57 | 137 | $51,375 | $7,888 | 15.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 13 | 32 | $16,160 | $3,044 | 18.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 31 | 76 | $39,520 | $5,230 | 13.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 50 | 118 | $41,890 | $5,159 | 12.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 15 | 25 | $12,375 | $2,405 | 19.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 11 | 23 | $3,755 | $1,105 | 29.4% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 15 | 20 | $2,115 | $484.19 | 22.9% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 12 | 12 | $2,580 | $293.16 | 11.4% |
About Dr. Rona Yaeger, M.D
Dr. Rona Yaeger, M.D is a Internal Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/14/2008. The National Provider Identifier (NPI) number assigned to this provider is 1790931384.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rona Yaeger, M.D has received a total of $68,115 in payments from pharmaceutical and medical device companies, with $25,348 received in 2024. These payments were reported across 71 transactions from 7 companies. The most common payment nature is "" ($56,535).
As a Medicare-enrolled provider, Yaeger has provided services to 515 Medicare beneficiaries, totaling 1,345 services with total Medicare billing of $97,726. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location New York, NY
- Active Since 08/14/2008
- Last Updated 07/08/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1790931384
Products in Payments
- BRAFTOVI (Drug) $46,255
- LUMAKRAS (Drug) $3,615
- KEYTRUDA (Biological) $1,108
- ELREXFIO (Drug) $940.00
- KRAZATI (Drug) $903.76
- MEKTOVI (Drug) $432.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New York
Dr. Stephen Saletan, M.d, M.D
Internal Medicine — Payments: $2.7M
Internal Medicine $2.7M
Michael Schuster, Md, MD
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Dr. Ziad Ali, Md Dphil, MD DPHIL
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Dr. James Underberg, Md, MD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M
Dr. Ricky Hsu, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Gail Roboz, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M